What is Glenmark Pharmaceuticals Ltd's market cap?

Glenmark Pharmaceuticals Ltd (GLENMARK) has a market capitalization of ₹60,645 Cr.

What sector is GLENMARK in?

Glenmark Pharmaceuticals Ltd operates in the Pharmaceuticals — Formulations & API sector.

What is GLENMARK's return on equity?

Glenmark Pharmaceuticals Ltd has a return on equity (ROE) of 11.1%.

Loading company...

Analyzing...

Glenmark Pharmaceuticals Ltd (GLENMARK) — Analysis, Financials, Intelligence | The Stock Filter

The Organism · Company Intelligence

Glenmark Pharmaceuticals Ltd

GLENMARK|BSE: 532296

Pharmaceuticals — Formulations & APIHealthcare & Life Scienceswww.glenmarkpharma.com

₹2,158.00

₹2.90 (-0.13%)|MCap ₹60,645 Cr

As of 16 Jun 2026 (End of Day)

Promoter: 46.6%Div Yield: 0.23%

52W Low ₹1,563.9052W High ₹2,474.00

PE 49.0xMedian PE 18.4xPB 6.5x

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and curr

Secular Currents

Theme Connections

Healthcare Access Pharma CDMO

Intelligence Profile

TSF Score

57/100

The Vitals · Company Health

Health Indicators

Shenanigan Score

5Clean

Trust Score

X-Ray

Concerns

No significant concerns identified

Watch

Nothing flagged for monitoring

Strengths

🟢Efficient capital deployment (ROCE: 15.3%)Business
🟢Low leverage (D/E: 0.09x)Business
🟢Consistent dividend payerOpportunity

The Numbers · Key Metrics

PE Ratio

49.0x

ROE

11.1%

Revenue Growth 3yr

2.5%

Debt/Equity

0.09x

₹58,969 Cr

The Narrator · StoryTel Intelligence

FY2025Pharmaceuticals — Formulations & APIProduct Sales ModelModel:Revenue = Volume of Drugs Sold × Average Selling Price (Domestic + Export)

Key Insight

“Operates in Pharmaceuticals — Formulations & API.”

The Revenue Story

₹13,322 Cr revenue.

Total Income₹13,435 Cr

Revenue₹13,322 Cr(99.2% of Total Income)

Other Income₹114 Cr(0.8% of Total Income)

The Cost Story

COGS 32.7%, employees 22.7%.

Cogs₹4,353 Cr(30.8%)

Other Expenses₹3,595 Cr(25.4%)

Employee₹3,022 Cr(21.4%)

EBITDA₹2,465 Cr(17.4%)

Depreciation₹486 Cr(3.4%)

Finance Costs₹207 Cr(1.5%)

0.1%EBITDA Margin

Cogs

30.8%

Other Expenses

25.4%

Employee

21.4%

EBITDA

17.4%

Depreciation

3.4%

Finance Costs

1.5%

Key Metrics

ROE

11.1%

vs median 10.5%

ROCE

15.3%

vs median 13.8%

Net Margin

6.4%

vs median 8.7%

EBITDA Margin

14.3%

vs median 16.0%

Debt To Equity

0.09x

vs median 0.21x

Rev Growth 3yr

2.5%

vs median 5.8%

EPS Growth 3yr

3.6%

vs median 3.6%

Forward View · Management Guidance

FINANCIALQ3FY26— 1High Impact

“nine months of FY '26, Glenmark's consolidated revenue is at rupees 1 lakh 32,119 million as against rupees 1 lakh, $655,000,000, recording a Y o Y growth of 31.”

FINANCIALQ3FY26— 1High Impact

“YOY growth of 15.1%. For the nine months of FY '26, Glenmark's consolidated revenue is at rupees 1 lakh 32,119 million as against rupees 1 lakh, $655,000,000, recording a Y o Y growth of 31.”

GUIDANCEQ3FY26— 2High Impact

“we expect a strong finish to FY 'twenty six with a good growth particularly in The U.”

The Context · Where does it sit?

Sector Context

The Canopy · Sector KPIs

Sector KPIs

Pharmaceuticals — Formulations & API

KPI	Company	Sector Median
ROE	11.1%▲	10.5%
ROCE	15.3%▲	13.8%
Net Margin	6.4%▼	8.7%
EBITDA Margin	14.3%▼	16.0%
Debt To Equity	0.09x▼	0.21x
Rev Growth 3yr	2.5%▼	5.8%
EPS Growth 3yr	3.6%	3.6%

The Market · What is the market saying?

Market Signals

The Antenna · Media Intelligence

Media Signal

Moderate Impact

7d-0.54→30d-0.54

Based on 4 articles (0 in last 7 days)

The Numbers · Show me the data

Financials

Revenue₹16,468 Cr

PBT₹1,605 Cr

EPS₹37.74

(₹ Cr)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	₹16,468 Cr +23.6%	₹13,322 Cr +12.8%	₹11,813 Cr -9.1%	₹12,990 Cr +5.6%	₹12,305 Cr +12.4%	₹10,944 Cr +2.8%	₹10,641 Cr +7.9%	₹9,865 Cr
Other Income	₹283 Cr +149.0%	₹114 Cr -86.5%	₹840 Cr +165.2%	₹317 Cr +90.1%	₹167 Cr +231.9%	₹50 Cr -68.5%	₹160 Cr -23.3%	₹208 Cr
Total Income	₹16,751 Cr +24.7%	₹13,435 Cr +6.2%	₹12,653 Cr -4.9%	₹13,307 Cr +6.7%	₹12,472 Cr +13.4%	₹10,994 Cr +1.8%	₹10,801 Cr +7.2%	₹10,074 Cr
COGS	₹4,664 Cr +7.1%	₹4,353 Cr -1.4%	₹4,413 Cr -2.7%	₹4,537 Cr +3.5%	₹4,385 Cr +18.6%	₹3,699 Cr +0.0%	₹3,699 Cr +10.0%	₹3,362 Cr
	₹12,881 Cr +10.4%	₹11,663 Cr -0.4%	₹11,716 Cr +0.4%	₹11,673 Cr +8.4%	₹10,769 Cr +11.5%	₹9,656 Cr -0.8%	₹9,737 Cr +8.9%	₹8,940 Cr
Profit Before Tax	₹1,605 Cr +14.7%	₹1,399 Cr	₹36 Cr -95.8%	₹868 Cr -39.7%	₹1,441 Cr +4.3%	₹1,382 Cr +26.1%	₹1,096 Cr -15.7%	₹1,301 Cr
Exceptional Items	(₹2,266 Cr) -507.7%	(₹373 Cr) +58.6%	(₹901 Cr) -17.6%	(₹766 Cr) -193.5%	(₹261 Cr) ↓ Decline	₹45 Cr +35.5%	₹33 Cr -80.3%	₹167 Cr
	₹540 Cr +53.4%	₹352 Cr -81.1%	₹1,867 Cr +280.3%	₹491 Cr +9.7%	₹448 Cr +8.5%	₹412 Cr +28.8%	₹320 Cr -14.8%	₹376 Cr
Net Profit	₹1,065 Cr +1.7%	₹1,047 Cr ↑ Recovery	(₹1,434 Cr) ↓ Decline	₹377 Cr -62.0%	₹994 Cr +2.4%	₹970 Cr +25.0%	₹776 Cr -16.1%	₹925 Cr
Profit (Owners)	₹1,065 Cr +1.7%	₹1,047 Cr ↑ Recovery	(₹1,502 Cr) ↓ Decline	₹377 Cr -59.9%	₹942 Cr -2.9%	₹970 Cr +25.0%	₹776 Cr -16.1%	₹925 Cr
Minority Interest	(₹0.07 Cr) ↓ Decline	₹0.04 Cr -99.9%	₹68 Cr	₹0.00 Cr -100.0%	₹52 Cr	₹0.00 Cr	₹0.00 Cr	₹0.00 Cr
Other Comprehensive Income	₹483 Cr +652.9%	₹64 Cr ↑ Recovery	(₹66 Cr) ↓ Decline	₹154 Cr +100.4%	₹77 Cr -11.5%	₹87 Cr ↑ Recovery	(₹246 Cr) +40.8%	(₹415 Cr)
EPS	₹37.74	₹37.11	(₹53.22)	₹13.38	₹33.37	₹34.38	₹27.50	₹32.78
Diluted Shares	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr